In summary, we identified MTOR as a key gene, on which pre-B-ALL are dependent on for proliferation and survival in vitro and in vivo and we provided a rationale for the combination of AKT and MTOR inhibitors in the treatment of a subset of pre B-ALL. Here, MTOR is linked to acute lymphoblastic leukemia.